• Accueil
• tpex
• Modified TPEx as First-line Treatment for Recurrent and/or Metastatic Head and Neck Cancer

Modified TPEx as First-line Treatment for Recurrent and/or Metastatic Head and Neck Cancer

4.6 (362) · € 23.00 · En Stock

Frontiers Identification of a Prognostic Clinical Score for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Systemic Therapy Including Cetuximab

JCM, Free Full-Text

Cancers, Free Full-Text

Main clinical trials evaluating the efficacy of new schemes of

Cancers, Free Full-Text

Treatment response lowers tumor symptom burden in recurrent and/or metastatic head and neck cancer, BMC Cancer

Cancers, Free Full-Text

Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for treatment of recurrent or metastatic head and neck squamous cell carcinoma: a systematic review and network meta-analysis - Zhe Jin, Bin Zhang, Lu Zhang

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised